Association of thyroid-stimulating hormone with corrected QT interval variation: A prospective cohort study among patients with type 2 diabetes.

Allongement de l’intervalle QT Arrhythmias Arythmies Diabetes Diabète Electrocardiogram QT prolongation Thyroid-stimulating hormone Thyrotropine Électrocardiogramme

Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 16 04 2021
revised: 31 05 2021
accepted: 14 06 2021
pubmed: 22 9 2021
medline: 1 12 2021
entrez: 21 9 2021
Statut: ppublish

Résumé

Patients with type 2 diabetes mellitus (T2DM) have a prolonged QT interval and are at high risk of sudden cardiac death. A prolonged QT interval, indicative of impaired ventricular repolarization, is a risk factor for lethal ventricular arrhythmias, such as torsades-de-pointes (TdP). To identify key clinical and biochemical covariates associated with Fridericia's corrected QT interval (QTcF) among euthyroid patients with T2DM, and to describe the temporal relationship between these factors and QTcF. We performed prospective, clinical, biochemical and electrocardiographic measurements among patients with T2DM enrolled in the DIACART study at Pitié-Salpêtrière Hospital, at T1 (baseline) and T2 (follow-up), with a median interval of 2.55 years. Mean age (63.9±8.5 years), sex (22.35% women), drugs with known risk of TdP according to the CredibleMeds website (Cred-drugsTdP) and serum thyroid-stimulating hormone (TSH) concentrations correlated with QTcF in univariate analysis at both T1 and T2. In multivariable analysis, all these covariates except age were significantly associated with QTcF at both T1 (women: standardized β=0.24±0.07, P=0.001; Cred-drugsTdP: β=0.19±0.07, P=0.007; TSH concentration: β=0.18±0.07, P=0.01) and T2 (women: β=0.25±0.08, P=0.002; Cred-drugsTdP: β=0.25±0.08, P=0.001; TSH concentration: β=0.19±0.08, P=0.01). Furthermore, variation in QTcF over the years was associated with variation in TSH concentration (r=0.24, P=0.007) and changes in use of Cred-drugsTdP (r=0.2, P=0.02). Serum TSH concentration and its variation were associated with QTcF and its variation, even after correcting for the main determinants of QTcF. Interventional optimization of TSH concentration in T2DM warrants further investigation to establish its impact on the risk of TdP and sudden cardiac death.

Sections du résumé

BACKGROUND BACKGROUND
Patients with type 2 diabetes mellitus (T2DM) have a prolonged QT interval and are at high risk of sudden cardiac death. A prolonged QT interval, indicative of impaired ventricular repolarization, is a risk factor for lethal ventricular arrhythmias, such as torsades-de-pointes (TdP).
AIMS OBJECTIVE
To identify key clinical and biochemical covariates associated with Fridericia's corrected QT interval (QTcF) among euthyroid patients with T2DM, and to describe the temporal relationship between these factors and QTcF.
METHODS METHODS
We performed prospective, clinical, biochemical and electrocardiographic measurements among patients with T2DM enrolled in the DIACART study at Pitié-Salpêtrière Hospital, at T1 (baseline) and T2 (follow-up), with a median interval of 2.55 years.
RESULTS RESULTS
Mean age (63.9±8.5 years), sex (22.35% women), drugs with known risk of TdP according to the CredibleMeds website (Cred-drugsTdP) and serum thyroid-stimulating hormone (TSH) concentrations correlated with QTcF in univariate analysis at both T1 and T2. In multivariable analysis, all these covariates except age were significantly associated with QTcF at both T1 (women: standardized β=0.24±0.07, P=0.001; Cred-drugsTdP: β=0.19±0.07, P=0.007; TSH concentration: β=0.18±0.07, P=0.01) and T2 (women: β=0.25±0.08, P=0.002; Cred-drugsTdP: β=0.25±0.08, P=0.001; TSH concentration: β=0.19±0.08, P=0.01). Furthermore, variation in QTcF over the years was associated with variation in TSH concentration (r=0.24, P=0.007) and changes in use of Cred-drugsTdP (r=0.2, P=0.02).
CONCLUSIONS CONCLUSIONS
Serum TSH concentration and its variation were associated with QTcF and its variation, even after correcting for the main determinants of QTcF. Interventional optimization of TSH concentration in T2DM warrants further investigation to establish its impact on the risk of TdP and sudden cardiac death.

Identifiants

pubmed: 34544648
pii: S1875-2136(21)00131-5
doi: 10.1016/j.acvd.2021.06.008
pii:
doi:

Substances chimiques

Thyrotropin 9002-71-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

656-666

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Rashmi Madhukar (R)

Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India; Department of Pharmacology and Clinical Investigation Centre (CIC-1901), Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, inserm, 75013 Paris, France.

Akshay T Jagadeesh (AT)

Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India; Department of Pharmacology and Clinical Investigation Centre (CIC-1901), Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, inserm, 75013 Paris, France.

Melissa Yen Yen Moey (MYY)

Department of Cardiovascular Sciences, East Carolina University, Greenville; and Vidant Medical Center, Greenville, NC 27834, USA.

Martino Vaglio (M)

AMPS LLC, New York, NY 10025, USA.

Fabio Badilini (F)

AMPS LLC, New York, NY 10025, USA.

Monique Leban (M)

Department of Biology, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, 75013 Paris, France.

Agnès Hartemann (A)

Department of Diabetology, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, inserm, 75013 Paris, France.

Pauline Dureau (P)

Department of Pharmacology and Clinical Investigation Centre (CIC-1901), Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, inserm, 75013 Paris, France.

Christian Funck-Brentano (C)

Department of Pharmacology and Clinical Investigation Centre (CIC-1901), Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, inserm, 75013 Paris, France.

Olivier Bourron (O)

Department of Diabetology, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, inserm, 75013 Paris, France.

Joe-Elie Salem (JE)

Department of Pharmacology and Clinical Investigation Centre (CIC-1901), Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, inserm, 75013 Paris, France; Departments of Medicine and Pharmacology, Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: joe-elie.salem@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH